ImpediMed enters into agreement with Mayo Clinic

Company News

by Jessica Ellerm

ImpediMed Limited (ASX:IPD) has announced it has entered into a 5 year master clinical trial agreement with the Mayo Clinic.
The trial will explore additional indications for its fluid status and body composition monitoring technology.
Clinical trials will be conducted at multiple U.S. locations and will also explore if the ImpediMed technology has wider applications in cardiology, nephrology, wellness and fitness.
Interim results from the trials are expected to be released late 2016.
ImpediMed Limited reported a net loss of $11.2 million at 31 December 2015.

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.